Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Healthtrust
Covington
US Department of Justice
Julphar
Baxter
Medtronic
Moodys

Generated: May 20, 2018

DrugPatentWatch Database Preview

EZETIMIBE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Ezetimibe patents expire, and when can generic versions of Ezetimibe launch?

Ezetimibe is a drug marketed by Alkem Labs Ltd, Amneal Pharms Co, Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Ohm Labs Inc, Sandoz Inc, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms Usa Inc, Watson Labs Teva, Dr Reddys Labs Sa, and Impax Labs Inc. and is included in sixteen NDAs.

The generic ingredient in EZETIMIBE is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Ten suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
Drug patent expirations by year for EZETIMIBE
Pharmacology for EZETIMIBE
Synonyms for EZETIMIBE
(-)-Sch 58235
(1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
(3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
(3R,4S)-1-(4-fluorophenyl)-3-[(3 S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)azetidin-2-one
(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
(3R,4S)-1-(4-Fluorophenyl)-3-[(S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-azetidin-2-one
(3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
163222-33-1
2-Azetidinone, 1-(4-fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3R,4S)-
2-Azetidinone, 1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3R-(3alpha(S*),4beta))-
222E331
28055-EP2272841A1
28055-EP2280001A1
28055-EP2287165A2
28055-EP2287166A2
28055-EP2292620A2
28055-EP2294052A1
28055-EP2295422A2
28055-EP2298742A1
28055-EP2298769A1
28055-EP2298776A1
28055-EP2301923A1
28055-EP2301936A1
28055-EP2308878A2
28055-EP2314588A1
AB0011316
AB00639916_09
AB00639916-06
AB00639916-08
AB2000199
ABP001091
AC-1057
AC1L442L
ACT03511
AKOS005572111
AM84560
AMX10142
AN-5188
BC216471
BDBM50371521
C24H21F2NO3
CAS-163222-33-1
CCG-100884
CHEBI:49040
CHEMBL1138
CPD000466334
CS-1016
D01966
D09LWS
DB00973
DR002439
DSSTox_CID_24223
DSSTox_GSID_44223
DSSTox_RID_80127
DTXSID1044223
EOR26LQQ24
Essex brand of ezetimibe
EX-A795
Ezedoc
ezentia
ezetimib
ezetimiba
Ezetimibe (JAN/USAN/INN)
Ezetimibe (Zetia)
Ezetimibe [USAN:INN:BAN]
Ezetimibe [USAN:INN]
Ezetimibe, >=98% (HPLC)
Ezetimibe, Pharmaceutical Secondary Standard; Certified Reference Material
Ezetimibe, United States Pharmacopeia (USP) Reference Standard
ezetimibum
Ezetrol
FT-0601590
GTPL6816
HE316388
HMS2051K16
HMS2236A04
HSDB 7737
HY-17376
Inegy (TN)
K-5098
KS-1170
LS-181801
MCULE-4417284526
Merck brand of ezetimibe
MFCD00937872
MK-0653
MLS000759443
MLS001424125
MLS006011921
MolPort-005-938-627
MSD brand of ezetimibe
NC00134
NCGC00095134-01
NCGC00263575-01
OLNTVTPDXPETLC-XPWALMASSA-N
RL02093
s1655
SAM001246623
SC-17354
Sch 58235
SCH-58235
SCH58235
SCHEMBL2871
Schering-Plough brand of ezetimibe
SMR000466334
STK640490
STOCK6S-73750
Tox21_111443
Tox21_111443_1
UNII-EOR26LQQ24
Vytorin (TN)
Z1550648770
Zetia
Zetia , Ezetrol, Ezetimibe
Zetia ;Ezetrol
Zetia (TN)
Zient
ZINC3810860

US Patents and Regulatory Information for EZETIMIBE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs Inc EZETIMIBE AND SIMVASTATIN ezetimibe; simvastatin TABLET;ORAL 202968-002 Apr 26, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Impax Labs Inc EZETIMIBE AND SIMVASTATIN ezetimibe; simvastatin TABLET;ORAL 201890-002 Apr 26, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs Inc EZETIMIBE AND SIMVASTATIN ezetimibe; simvastatin TABLET;ORAL 202968-003 Apr 26, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Impax Labs Inc EZETIMIBE AND SIMVASTATIN ezetimibe; simvastatin TABLET;ORAL 201890-003 Apr 26, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Dow
Deloitte
Covington
Cantor Fitzgerald
Cerilliant
Argus Health
Chubb
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.